The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies
| dc.contributor.author | Li, Zenggang | |
| dc.contributor.author | Ivanov, Andrei A. | |
| dc.contributor.author | Su, Rina | |
| dc.contributor.author | González-Pecchi, Valentina | |
| dc.contributor.author | Qi, Qi | |
| dc.contributor.author | Liu, Songlin | |
| dc.contributor.author | Webber, Philip J. | |
| dc.contributor.author | McMillan, Elizabeth A. | |
| dc.contributor.author | Rusnak, Lauren E. | |
| dc.contributor.author | Pham, Cau Dinh | |
| dc.contributor.author | Chen, Xiaoqian | |
| dc.contributor.author | Mo, Xiulei | |
| dc.contributor.author | Revennaugh, Brian | |
| dc.contributor.author | Zhou, Wei | |
| dc.contributor.author | Marcus, Adam I. | |
| dc.contributor.author | Harati, Sahar | |
| dc.contributor.author | Chen, Xiang | |
| dc.contributor.author | Johns, Margaret A. | |
| dc.contributor.author | White, Michael A. | |
| dc.contributor.author | Moreno, Carlos S. | |
| dc.contributor.author | Cooper, Lee Alex Donald | |
| dc.contributor.author | Du, Yuhong | |
| dc.contributor.author | Khuri, Fadlo R. | |
| dc.contributor.author | Fu, Haian | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:50:25Z | |
| dc.date.available | 2025-01-24T11:50:25Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | As genomics advances reveal the cancer gene landscape, a daunting task is to understand how these genes contribute to dysregulated oncogenic pathways. Integration of cancer genes into networks offers opportunities to reveal protein-protein interactions (PPIs) with functional and therapeutic significance. Here, we report the generation of a cancer-focused PPI network, termed OncoPPi, and identification of >260 cancer-associated PPIs not in other large-scale interactomes. PPI hubs reveal new regulatory mechanisms for cancer genes like MYC, STK11, RASSF1 and CDK4. As example, the NSD3 (WHSC1L1)-MYC interaction suggests a new mechanism for NSD3/BRD4 chromatin complex regulation of MYC-driven tumours. Association of undruggable tumour suppressors with drug targets informs therapeutic options. Based on OncoPPi-derived STK11-CDK4 connectivity, we observe enhanced sensitivity of STK11-silenced lung cancer cells to the FDA-approved CDK4 inhibitor palbociclib. OncoPPi is a focused PPI resource that links cancer genes into a signalling network for discovery of PPI targets and network-implicated tumour vulnerabilities for therapeutic interrogation. © 2017 The Author(s). | |
| dc.identifier.doi | https://doi.org/10.1038/ncomms14356 | |
| dc.identifier.eid | 2-s2.0-85013213267 | |
| dc.identifier.pmid | 28205554 | |
| dc.identifier.uri | http://hdl.handle.net/10938/30946 | |
| dc.language.iso | en | |
| dc.publisher | Nature Publishing Group | |
| dc.relation.ispartof | Nature Communications | |
| dc.source | Scopus | |
| dc.subject | Cell line, tumor | |
| dc.subject | Cell survival | |
| dc.subject | Cyclin-dependent kinase 4 | |
| dc.subject | Databases, protein | |
| dc.subject | Gene expression regulation, neoplastic | |
| dc.subject | Gene regulatory networks | |
| dc.subject | Genes, myc | |
| dc.subject | Genes, tumor suppressor | |
| dc.subject | Genomics | |
| dc.subject | Histone-lysine n-methyltransferase | |
| dc.subject | Humans | |
| dc.subject | Lung neoplasms | |
| dc.subject | Molecular targeted therapy | |
| dc.subject | Neoplasm proteins | |
| dc.subject | Nuclear proteins | |
| dc.subject | Oncogenes | |
| dc.subject | Protein interaction domains and motifs | |
| dc.subject | Protein interaction mapping | |
| dc.subject | Protein kinase inhibitors | |
| dc.subject | Protein stability | |
| dc.subject | Protein-serine-threonine kinases | |
| dc.subject | Signal transduction | |
| dc.subject | Transcription factors | |
| dc.subject | Tumor suppressor proteins | |
| dc.subject | Cyclin dependent kinase 4 | |
| dc.subject | Myc protein | |
| dc.subject | Palbociclib | |
| dc.subject | Protein kinase lkb1 | |
| dc.subject | Ras association domain family protein 1a | |
| dc.subject | Brd4 protein, human | |
| dc.subject | Cdk4 protein, human | |
| dc.subject | Histone lysine methyltransferase | |
| dc.subject | Nuclear protein | |
| dc.subject | Protein kinase inhibitor | |
| dc.subject | Protein serine threonine kinase | |
| dc.subject | Rassf1 protein, human | |
| dc.subject | Stk11 protein, human | |
| dc.subject | Transcription factor | |
| dc.subject | Tumor protein | |
| dc.subject | Tumor suppressor protein | |
| dc.subject | Whsc1l1 protein, human | |
| dc.subject | Cancer | |
| dc.subject | Cells and cell components | |
| dc.subject | Drug | |
| dc.subject | Gene | |
| dc.subject | Inhibitor | |
| dc.subject | Protein | |
| dc.subject | Tumor | |
| dc.subject | Article | |
| dc.subject | Cancer genetics | |
| dc.subject | Chromatin | |
| dc.subject | Controlled study | |
| dc.subject | Gene silencing | |
| dc.subject | Human | |
| dc.subject | Human cell | |
| dc.subject | Information system | |
| dc.subject | Protein protein interaction | |
| dc.subject | Regulatory mechanism | |
| dc.subject | Tumor gene | |
| dc.subject | Tumor suppressor gene | |
| dc.subject | Drug effect | |
| dc.subject | Gene expression regulation | |
| dc.subject | Gene regulatory network | |
| dc.subject | Genetics | |
| dc.subject | Lung tumor | |
| dc.subject | Metabolism | |
| dc.subject | Molecularly targeted therapy | |
| dc.subject | Oncogene | |
| dc.subject | Oncogene myc | |
| dc.subject | Physiology | |
| dc.subject | Protein analysis | |
| dc.subject | Protein database | |
| dc.subject | Protein domain | |
| dc.subject | Tumor cell line | |
| dc.title | The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1